Galderma, an independent dermatology company, announces that it has received antitrust clearance from the US authorities and has completed the acquisition of ALASTIN Skincare Inc, a specialty aesthetics company that develops physician-dispensed skincare products. The transaction was previously announced on November 29, 2021.
“I am so happy to officially welcome the ALASTIN team to Galderma. As a part of our integrated dermatology approach, we are continuously seeking to add products that synergize with our premium portfolio – and ALASTIN is the perfect fit.
The ALASTIN brand’s proprietary and award-winning skincare technology, combined with Galderma’s world-class pipeline and innovation track record, represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients, now and well into the future.”— Flemming Ørnskov, MD, MPH, Chief Executive Officer, Galderma
ALASTIN’s product offerings are backed by the patented TriHex Technology, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. This acquisition will enhance Galderma’s integrated dermatology platform with a comprehensive collection of scientifically proven products for daily skincare regimens and peri-procedural use, and underscores the company’s commitment to be the partner of choice for aesthetic professionals.
“Our team is extremely excited to be joining the Galderma family, and our shared focus on customers and commitment to driving innovation means we’re a winning combination. Galderma’s global reach and cutting-edge research and development platform will help deliver ALASTIN’s next growth phase and support further innovation of ALASTIN’s products.”— Diane S Goostree, President and CEO, ALASTIN Skincare